Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
exoSTING in advanced solid tumors
NCT04592484Phase 2Completed
- Sponsor
- Codiak BioSciences
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of exoSTING in solid tumor, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), anaplastic thyroid carcinoma (ATC), cutaneous squamous cell carcinoma (cSCC), sponsored by Codiak BioSciences. Started Sep 2020; status: completed.
02
Drugs
exoSTING
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)anaplastic thyroid carcinoma (ATC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04592484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592484.